CA3235381A1 - Formulations - Google Patents
Formulations Download PDFInfo
- Publication number
- CA3235381A1 CA3235381A1 CA3235381A CA3235381A CA3235381A1 CA 3235381 A1 CA3235381 A1 CA 3235381A1 CA 3235381 A CA3235381 A CA 3235381A CA 3235381 A CA3235381 A CA 3235381A CA 3235381 A1 CA3235381 A1 CA 3235381A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- buffer
- glycine
- naci
- stable liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115121.2 | 2021-10-21 | ||
| GBGB2115121.2A GB202115121D0 (en) | 2021-10-21 | 2021-10-21 | Formulations |
| PCT/EP2022/079182 WO2023067049A1 (en) | 2021-10-21 | 2022-10-20 | Formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235381A1 true CA3235381A1 (en) | 2023-04-27 |
Family
ID=78806158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235381A Pending CA3235381A1 (en) | 2021-10-21 | 2022-10-20 | Formulations |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240415769A1 (https=) |
| EP (1) | EP4419078A1 (https=) |
| JP (1) | JP2024539265A (https=) |
| KR (1) | KR20240099311A (https=) |
| CN (1) | CN118119377A (https=) |
| AR (1) | AR127421A1 (https=) |
| AU (1) | AU2022372646A1 (https=) |
| CA (1) | CA3235381A1 (https=) |
| CL (1) | CL2024001229A1 (https=) |
| CO (1) | CO2024006193A2 (https=) |
| GB (1) | GB202115121D0 (https=) |
| GE (2) | GEAP202416520A (https=) |
| IL (1) | IL312207A (https=) |
| MX (1) | MX2024004872A (https=) |
| PE (1) | PE20241193A1 (https=) |
| TW (1) | TW202323288A (https=) |
| WO (1) | WO2023067049A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| GB201209096D0 (en) | 2012-05-24 | 2012-07-04 | Medical Res Council Technology | Compounds |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
-
2021
- 2021-10-21 GB GBGB2115121.2A patent/GB202115121D0/en not_active Ceased
-
2022
- 2022-10-20 JP JP2024524494A patent/JP2024539265A/ja active Pending
- 2022-10-20 US US18/703,661 patent/US20240415769A1/en active Pending
- 2022-10-20 MX MX2024004872A patent/MX2024004872A/es unknown
- 2022-10-20 CN CN202280070135.8A patent/CN118119377A/zh active Pending
- 2022-10-20 GE GEAP202416520A patent/GEAP202416520A/en unknown
- 2022-10-20 KR KR1020247016530A patent/KR20240099311A/ko active Pending
- 2022-10-20 AR ARP220102861A patent/AR127421A1/es unknown
- 2022-10-20 IL IL312207A patent/IL312207A/en unknown
- 2022-10-20 TW TW111139753A patent/TW202323288A/zh unknown
- 2022-10-20 GE GEAP202216520A patent/GEP20257800B/en unknown
- 2022-10-20 EP EP22817522.0A patent/EP4419078A1/en active Pending
- 2022-10-20 PE PE2024000910A patent/PE20241193A1/es unknown
- 2022-10-20 CA CA3235381A patent/CA3235381A1/en active Pending
- 2022-10-20 WO PCT/EP2022/079182 patent/WO2023067049A1/en not_active Ceased
- 2022-10-20 AU AU2022372646A patent/AU2022372646A1/en active Pending
-
2024
- 2024-04-19 CL CL2024001229A patent/CL2024001229A1/es unknown
- 2024-05-16 CO CONC2024/0006193A patent/CO2024006193A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022372646A1 (en) | 2024-06-06 |
| GEAP202416520A (en) | 2024-07-25 |
| AR127421A1 (es) | 2024-01-24 |
| GB202115121D0 (en) | 2021-12-08 |
| GEP20257800B (en) | 2025-09-25 |
| CN118119377A (zh) | 2024-05-31 |
| JP2024539265A (ja) | 2024-10-28 |
| TW202323288A (zh) | 2023-06-16 |
| KR20240099311A (ko) | 2024-06-28 |
| US20240415769A1 (en) | 2024-12-19 |
| MX2024004872A (es) | 2024-05-06 |
| PE20241193A1 (es) | 2024-06-03 |
| IL312207A (en) | 2024-06-01 |
| EP4419078A1 (en) | 2024-08-28 |
| CL2024001229A1 (es) | 2024-09-13 |
| CO2024006193A2 (es) | 2024-05-30 |
| WO2023067049A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101782203B1 (ko) | 동결건조 및 수성 항-cd40 항체 제제 | |
| JP5513380B2 (ja) | 肝細胞増殖因子に対する特異的結合剤の組成物 | |
| US20060008415A1 (en) | Stable liquid and lyophilized formulation of proteins | |
| KR20190142393A (ko) | 항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법 | |
| JP2018507202A (ja) | モノクローナル抗体のための安定的な液体製剤 | |
| KR20140066124A (ko) | 점도가 감소된 제제 | |
| US20240342083A1 (en) | Anti-pd-1 antibody pharmaceutical composition and use thereof | |
| KR20140018966A (ko) | 점도가 감소된 제제 | |
| JP2018531980A (ja) | 抗ｄ因子抗体製剤 | |
| JP2023535433A (ja) | Ｐｄ－ｌ１／ｌａｇ－３二重特異性抗体製剤およびその調製方法ならびに使用 | |
| US20250282882A1 (en) | Pharmaceutical formulation comprising anti-ox40 monoclonal antibody | |
| CA3235381A1 (en) | Formulations | |
| AU2022369042A1 (en) | Formulations | |
| HK40109650A (zh) | 制剂 | |
| HK40109619A (zh) | 制剂 | |
| RU2844800C2 (ru) | Фармацевтическая композиция на основе антитела против PD-1 и ее применение | |
| CA3211692A1 (en) | Formulations of anti-endothelial lipase antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240924 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240926 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250924 |